GWS
ABUS icon

Glassman Wealth Services’s Arbutus Biopharma ABUS Stock Holding History

Glassman Wealth Services’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,238
Closed -$4K – 1626
2022
Q1 		$4K Hold
1,238
– – ﹤0.01% 1035
2021
Q4 		$5K Buy
+1,238
New +$4.81K ﹤0.01% 960

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glassman Wealth Services's ABUS Position: Q2 2022 in Review

Glassman Wealth Services sold out of Arbutus Biopharma (ABUS) in Q2 2022, closing a stake of 1,238 shares — an estimated $4K sold.

Glassman Wealth Services first reported a position in ABUS in Q4 2021 and held it in 2 quarters. The position peaked at $5K in Q4 2021. 113 funds tracked by Wall St. Rank hold ABUS as of Q2 2022.

  • Glassman Wealth Services reported no remaining Arbutus Biopharma position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 1,238 Arbutus Biopharma shares in Q2 2022, an estimated $4K.
  • Glassman Wealth Services first reported a position in Arbutus Biopharma in Q4 2021 and held it in 2 quarters.
  • Glassman Wealth Services's Arbutus Biopharma position peaked at $5K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.